Cargando…
Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer
The androgen receptor (AR) is a key transcription factor in the initiation and progression of prostate cancer (PC) and is a major therapeutic target for the treatment of advanced disease. Unfortunately, current therapies are not curative for castration resistant PC and a better understanding of AR r...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741960/ https://www.ncbi.nlm.nih.gov/pubmed/26462181 |
_version_ | 1782414109409542144 |
---|---|
author | McClurg, Urszula L. Harle, Victoria J. Nabbi, Arash Batalha-Pereira, Amanda Walker, Scott Coffey, Kelly Gaughan, Luke McCracken, Stuart RC Robson, Craig N. |
author_facet | McClurg, Urszula L. Harle, Victoria J. Nabbi, Arash Batalha-Pereira, Amanda Walker, Scott Coffey, Kelly Gaughan, Luke McCracken, Stuart RC Robson, Craig N. |
author_sort | McClurg, Urszula L. |
collection | PubMed |
description | The androgen receptor (AR) is a key transcription factor in the initiation and progression of prostate cancer (PC) and is a major therapeutic target for the treatment of advanced disease. Unfortunately, current therapies are not curative for castration resistant PC and a better understanding of AR regulation could identify novel therapeutic targets and biomarkers to aid treatment of this disease. The AR is known to be regulated by a number of post-translational modifications and we have recently identified the deubiquitinating enzyme Usp12 as a positive regulator of AR. We determined that Usp12 deubiquitinates the AR resulting in elevated receptor stability and activity. Furthermore, Usp12 silencing was shown to reduce proliferation of PC cells. Usp12 is known to require the co-factors Uaf-1 and WDR20 for catalytic activity. In this report we focus further on the role of Uaf-1 and WDR20 in Usp12 regulation and investigate if these co-factors are also required for controlling AR activity. Firstly, we confirm the presence of the Usp12/Uaf-1/WDR20 complex in PC cells and demonstrate the importance of Uaf-1 and WDR20 for Usp12 stabilisation. Consequently, we show that individual silencing of either Uaf-1 or WDR20 is sufficient to abrogate the activity of the Usp12 complex and down-regulate AR-mediated transcription via receptor destabilisation resulting in increased apoptosis and decreased colony forming ability of PC cells. Moreover, expression of both Uaf-1 and WDR20 is higher in PC tissue compared to benign controls. Overall these results highlight the potential importance of the Usp12/Uaf-1/WDR20 complex in AR regulation and PC progression. Androgen receptor is a key transcriptional regulator in prostate cancer. Usp12/Uaf-1/WDR20 complex plays a crucial role in androgen receptor stability and activity. Destabilising an individual Usp12/Uaf-1/WDR20 complex member reduces the protein levels of the whole complex and diminishes androgen receptor activity. Protein levels of all members of the Usp12/Uaf-1/WDR20 complex are significantly increased in PC; |
format | Online Article Text |
id | pubmed-4741960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-47419602016-03-17 Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer McClurg, Urszula L. Harle, Victoria J. Nabbi, Arash Batalha-Pereira, Amanda Walker, Scott Coffey, Kelly Gaughan, Luke McCracken, Stuart RC Robson, Craig N. Oncotarget Research Paper The androgen receptor (AR) is a key transcription factor in the initiation and progression of prostate cancer (PC) and is a major therapeutic target for the treatment of advanced disease. Unfortunately, current therapies are not curative for castration resistant PC and a better understanding of AR regulation could identify novel therapeutic targets and biomarkers to aid treatment of this disease. The AR is known to be regulated by a number of post-translational modifications and we have recently identified the deubiquitinating enzyme Usp12 as a positive regulator of AR. We determined that Usp12 deubiquitinates the AR resulting in elevated receptor stability and activity. Furthermore, Usp12 silencing was shown to reduce proliferation of PC cells. Usp12 is known to require the co-factors Uaf-1 and WDR20 for catalytic activity. In this report we focus further on the role of Uaf-1 and WDR20 in Usp12 regulation and investigate if these co-factors are also required for controlling AR activity. Firstly, we confirm the presence of the Usp12/Uaf-1/WDR20 complex in PC cells and demonstrate the importance of Uaf-1 and WDR20 for Usp12 stabilisation. Consequently, we show that individual silencing of either Uaf-1 or WDR20 is sufficient to abrogate the activity of the Usp12 complex and down-regulate AR-mediated transcription via receptor destabilisation resulting in increased apoptosis and decreased colony forming ability of PC cells. Moreover, expression of both Uaf-1 and WDR20 is higher in PC tissue compared to benign controls. Overall these results highlight the potential importance of the Usp12/Uaf-1/WDR20 complex in AR regulation and PC progression. Androgen receptor is a key transcriptional regulator in prostate cancer. Usp12/Uaf-1/WDR20 complex plays a crucial role in androgen receptor stability and activity. Destabilising an individual Usp12/Uaf-1/WDR20 complex member reduces the protein levels of the whole complex and diminishes androgen receptor activity. Protein levels of all members of the Usp12/Uaf-1/WDR20 complex are significantly increased in PC; Impact Journals LLC 2015-10-10 /pmc/articles/PMC4741960/ /pubmed/26462181 Text en Copyright: © 2015 McClurg et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper McClurg, Urszula L. Harle, Victoria J. Nabbi, Arash Batalha-Pereira, Amanda Walker, Scott Coffey, Kelly Gaughan, Luke McCracken, Stuart RC Robson, Craig N. Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer |
title | Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer |
title_full | Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer |
title_fullStr | Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer |
title_full_unstemmed | Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer |
title_short | Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer |
title_sort | ubiquitin-specific protease 12 interacting partners uaf-1 and wdr20 are potential therapeutic targets in prostate cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741960/ https://www.ncbi.nlm.nih.gov/pubmed/26462181 |
work_keys_str_mv | AT mcclurgurszulal ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer AT harlevictoriaj ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer AT nabbiarash ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer AT batalhapereiraamanda ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer AT walkerscott ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer AT coffeykelly ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer AT gaughanluke ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer AT mccrackenstuartrc ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer AT robsoncraign ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer |